tradingview
Incannex Commences Screening in Phase 2 DReAMzz Study of IHL-42X for OSA
Incannex commenced participant screening in its DReAMzz Phase 2 dose confirmation study of IHL-42X, advancing the program toward Phase III.Key Highlights:Original SEC Filing: Incannex Healthcare Inc. [ IXHL ] - 8-K - Jul. 23, 2026This is an AI-powered summary. It may contain inaccuracies. Consider…